Kong et al. [27] demonstrated late-phase renal tubular HIF-2α activation to be protective for renal fibrosis and renal dysfunction, and also demonstrated its use as a therapeutic agent in the late phase of chronic kidney disease. Here, EPAS1 is linked to chronic kidney disease.